CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab

TY - JOUR

T1 - CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab

AU - de Vries Lentsch, Simone

AU - Al-Hassany, Linda

AU - Ferrari, Michel Dominique

AU - Terwindt, Gisela Marie

AU - MaassenVanDenBrink, Antoinette

N1 - Funding Information: This work was supported by grants of the Dutch Research Council (NWO; Spinoza Award 2009 to MDF and VICI grant 09150181910040 to AMVB). Funding Information: AMVB reports consultancy or industry support from Novartis, Lilly and Teva, who are all three companies that are marketing CGRP (receptor) monoclonal antibodies, and independent support from the Dutch Research Council and the Dutch Heart & Brain Foundations. GT reports consultancy support from Novartis, Lilly, Teva (see above), Allergan and independent support from Dutch Research Council, and the Dutch Heart & Brain Foundations. SdVL, LA-H and MDF have no conflict of interest to declare.

PY - 2022/8/1

Y1 - 2022/8/1

UR - http://www.scopus.com/inward/record.url?scp=85133871693&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2021-327992

DO - 10.1136/jnnp-2021-327992

M3 - Article

C2 - 35086941

AN - SCOPUS:85133871693

SN - 0022-3050

VL - 93

SP - 911

EP - 912

JO - Journal of neurology, neurosurgery, and psychiatry

JF - Journal of neurology, neurosurgery, and psychiatry

IS - 8

ER -